<DOC>
	<DOCNO>NCT02765204</DOCNO>
	<brief_summary>The purpose study evaluate Dapagliflozin direct effect alpha cell glucagon release .</brief_summary>
	<brief_title>A Single-dose Cross-over Study Assess Direct Indirect Effects Dapagliflozin Pancreatic Alpha Beta Cells Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>1 . Males female age 18 75 . 2 . Female subject must meet following criterion : 1 . Not breastfeed 2 . Negative pregnancy test result ( human chorionic gonadotropin , beta subunit [ hCG ] ) Visit 0 ( screen ) ( applicable hysterectomized female ) . 3 . If childbearing potential ( include perimenopausal woman menstrual period within 1 year ) , must practice willing continue practice one follow highly effective birth control method entire duration study : i. Diaphragm partner use condom combination combine ( estrogen progestogen contain ) hormonal contraception associate inhibition ovulation : Oral Intravaginal Transdermal ii . Diaphragm partner use condom combination progestogenonly hormonal contraception associate inhibition ovulation : Oral Injectable Implantable iii . Placement intrauterine device iv . Placement intrauterine hormonereleasing system v. Bilateral tubal occlusion vi . Vasectomised partner ( provided partner sole sexual partner female subject vasectomise partner receive medical assessment surgical success ) vii . Sexual abstinence ( define refrain heterosexual intercourse ) ) Must practice appropriate birth control state 10 week last dose study medication 3 . BMI 20 35 . 4 . Clinical T2D diagnosis least 6 month prior enrolment . 5 . Metformin treatment , stable dose least 1 month . 6 . HbA1c 55 86 mmol/mol ( 7,210 % DCCT ) . 1 . History sign clinically significant disease disorder , opinion investigator , may either put subject risk participation study , influence result subject 's ability participate study . 2 . Clinical diagnosis Type 1 diabetes mellitus and/or history diabetic ketoacidosis positive Glutamic Acid Decarboxylase Autoantibodies test ( GAD antibodies test ) . 3 . Patients treat antipsychotic , systemic glucocorticoid , neuropsychiatric stimulant , antidepressant sympathetic activity , beta blocker pharmaceutical render patient unfit study participation judge investigator . 4 . Patients treat antidiabetic medication Metformin . 5 . Patients endocrine disease except substituted hypothyroidism . 6 . Significant abnormal liver function define aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN . 7 . Patients impaired liver kidney function ( eGFR &lt; 60 ) . 8 . Known suspected history significant drug abuse . 9 . History alcohol abuse excessive intake alcohol judge investigator . 10 . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge investigator . 11 . Plasma donation within one month screen blood donation significant blood loss ( &gt; 400 ml ) 3 month prior screen . 12 . Any condition opinion investigator would render patient unsuitable inclusion study /or patient safety . 13 . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or staff study site ) . 14 . Judgment investigator subject participate study considers subject unlikely comply study procedure , restriction requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>